|
8th Annual Conference Of The British HIV Association [BHIVA]19 – 21 April 2002, University of York, York |
[AUTHOR(S):] M Brady, S Fidler, J Clarke, J Weber
Faculty of Medicine, St Mary's Hospital, Imperial College, London
BHIVA Conf 2002 Apr 19-21;8:O7
OBJECTIVE: To measure the prevalence of resistant HIV-1 virus strains in a cohort of patients with PHI, all within 6 months of seroconversion.
METHODS: PHI was defined as a negative HIV test in the previous 6 months, negative/evolving HIV antibody tests with positive HIV polymerase chain reaction (PCR) test and/or symptoms of HIV seroconversion. Genotypic resistance testing using ABI Viroseq version 2 was performed at baseline on all samples.
RESULTS: 46 patients have been recruited (44 gay men, 1 heterosexual man and 1 heterosexual woman). The median age (range) is 30 years (21–77). The median (range) CD4 count and viral load at baseline were 465 cells/µL (90–1200) and 122,298 RNA copies/mL (179 to >500,000). All infections were sexually transmitted. Baseline resistance results are available on all 46 patients. 42/46 (91.3%) were subtype B. All non-B subtype infections were acquired in Africa. 44/46 (95.6%) were wildtype virus. Only two patients in the cohort (4.3%) had acquired a drugresistant virus. Both are gay men, one infected in Australia and one in the UK. The first had mutations M184V, G196E, L63P, G73S, V77I and L90M, while the second had M41L, A98G, M184V, Y188L and T215Y mutations.
CONCLUSIONS: We report a much lower prevalence of drug-resistant virus in primary infection compared with previous studies. Transmission of drug-resistant virus appears to be an increasing problem and rapid genotypic resistant testing is essential in the context of treating primary HIV-1 infection.
PRESENTING AUTHOR: M Brady
020419
O7
Copyright © 2002 - British HIV Association (BHIVA) Reproduction of this abstract (other than one copy for personal reference) must be cleared through the BHIVA Organising Secretariat 1 Mountview Court, 310 Friern Barnet Lane, London N20 0LD